Scientific Publications
THOR-707, a Novel Not-alpha IL-2, Promotes All Key Immune System Anti-tumoral Actions of IL-2
Without Eliciting Vascular Leak Syndrome (VLS)
September 30, 2019
European Society for Medical Oncology (ESMO) 2019 Congress
THOR-809: An IL-2 Engineered From an Expanded Genetic Alphabet for the Potential Treatment of Autoimmune Disorders
September 16, 2019
14th World Congress on Inflammation 2019
THOR-707: Using Synthetic Biology to Reprogram the Therapeutic Activity of Interleukin-2 (IL-2)
June 1, 2019
2019 American Society of Clinical Oncology (ASCO) Annual Meeting
THOR-707, A Novel Not-alpha IL-2, Elicits Durable Pharmacodynamic Responses in Non-human Primates and Efficacy as Single Agent and in Combination with Anti PD-1 in Multiple Syngeneic Mouse Models
April 2, 2019
American Association for Cancer Research (AACR) Annual Meeting 2019
THOR-707, an engineered not-alpha IL-2, for the treatment of solid tumors induces strong immunological responses in vivo
March 22-23, 2019
Chinese Society for Clinical Oncology (CSCO) Conference on Immunotherapy – Endorsed by the American Association for Cancer Research (AACR)
THOR-707: An Engineered IL-2 for the Treatment of Solid Tumors with Superior Pre-Clinical Efficacy and Safety Evidence
November 9, 2018
2018 Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting
A semi-synthetic organism that stores and retrieves increased genetic information
November 30, 2017
Y. Zhang, J.L. Ptacin, E.C. Fischer, H.R. Aerni, C.E. Caffaro, K. San Jose, A.W. Feldman, C.R. Turner, F.E. Romesberg. Nature (2017) 551:644-647.